Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Audentes Set To Resume XLMTM Trial As US Hold Lifts

Talks With Regulators On Way Forward

Executive Summary

Trial of high-need gene therapy set to restart following the deaths of several participants and the lifting of a clinical hold imposed by the US FDA last year.

You may also be interested in...



Shape Therapeutics’ Big Financing Shows Growing Interest In Novel Capsids

Several companies have recently raised large amounts of money from venture capital as well as potentially through partnerships for next-generation capsid technology.

Astellas Eyes Doubling Market Cap On Core, Focus Assets

Astellas lays out new mid-term strategic plan it sees as overcoming looming major expiries while positioning the firm for growth in new areas and a more than doubling in market cap.

Biogen/Capsigen Ink Up To $1.3bn Deal For Improved AAV Capsids

Biogen is Capsigen’s first partner, while Dyno Therapeutics has also entered into deals potentially worth billions with large drug and biotech firms.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143567

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel